Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20745593 | 0.87 | LMNA (0.45) | LMNAKDM4ESMN1; SMN2KMT2AMAPT | |
| SCHEMBL20745289 | 0.85 | LMNA (0.58) | LMNAKDM4ESMN1; SMN2KMT2AMAPT | |
| SCHEMBL31338415 | 0.84 | LMNA (0.50) | LMNAKDM4ESMN1; SMN2KMT2AMAPT | |
| SCHEMBL20745714 | 0.83 | LMNA (0.42) | LMNAKDM4ESMN1; SMN2MAPTMAPK1 | |
| SCHEMBL31338386 | 0.83 | LMNA (0.56) | LMNAKDM4ESMN1; SMN2KMT2AMAPT | |
| SCHEMBL20745518 | 0.82 | ALDH1A1 (0.47) | LMNAKDM4ESMN1; SMN2KMT2AMAPT | |
| SCHEMBL20745645 | 0.80 | ALDH1A1 (0.44) | LMNAKDM4ESMN1; SMN2KMT2AMAPT | |
| SCHEMBL20745576 | 0.79 | LMNA (0.41) | LMNAKDM4ESMN1; SMN2KMT2AMAPT | |
| SCHEMBL20745455 | 0.77 | KDM4E (0.52) | LMNAKDM4ESMN1; SMN2KMT2AMAPT | |
| SCHEMBL31338390 | 0.75 | LMNA (0.50) | LMNAKDM4ESMN1; SMN2KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739658-A1 | SYNTHESIS OF PYRUVATE KINASE ACTIVATORS | Agios Pharmaceuticals, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250144093-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2025-05-08 | — | — | US | disclosed |
| WO-2025010390-A1 | SYNTHESIS OF PYRUVATE KINASE ACTIVATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| US-12133853-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-11957680-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| CN-117186119-A | Pyruvate kinase activators for the treatment of hematological disorders | 安吉奥斯医药品有限公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-3668881-B1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20200206225-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200207785-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PHARMARESOURCES (SHANGHAI) CO., LTD. (CN) | 2020-07-02 | — | — | US | disclosed |
| US-20200206225-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| EP-3668513-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | Agios Pharmaceuticals, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668512-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | Agios Pharmaceuticals, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668881-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | Agios Pharmaceuticals, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| CN-111032046-A | Pyruvate kinase modulators and uses thereof | 安吉奥斯医药品有限公司 | 2020-04-17 | — | — | CN | disclosed |
| WO-2019035864-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035865-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035863-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | PDK1, PDK2, PDK4 | LMNA 1466/4885KDM4E 692/4885SMN1; SMN2 3229/4885 |
| US-20200206225-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | PDK1, PDK2, PDK4 | LMNA 1466/4885KDM4E 692/4885SMN1; SMN2 3229/4885 |
| US-11957680-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | LMNA 1137/4885KDM4E 2025/4885SMN1; SMN2 1871/4885 |
| US-12133853-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | LMNA 1651/4885KDM4E 1481/4885SMN1; SMN2 2980/4885 |
| US-20200207785-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | LMNA 1559/4885KDM4E 1713/4885SMN1; SMN2 2795/4885 |
| US-20250144093-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | LMNA 1651/4885KDM4E 1481/4885SMN1; SMN2 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.